Levofloxacin, 5 mg/ml 100 ml

A broad-spectrum antimicrobial agent, a fluoroquinolone. It acts bactericidally. It blocks DNA-enzyme (topoisomerase II) and topoisomerase IV, disrupts superspiralization and cross-linking of DNA breaks, inhibits DNA synthesis, causes deep morphological changes in cytoplasm, cell wall and membranes.

. Active against Enterococcus faecalis, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus agalactiae, Viridans group streptococci, Enterobacter cloacae, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter sakazakii, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Klebsiella oxytoca, Legionella pneumoniae, Moraxella catarrhalis, Proteus mirabilis, Pseudomonas aeruginosa, Pseudomonas fluorescens, Chlamydia pneumoniae, Mycoplasma pneumoniae, Acinetobacter anitratus, Acinetobacter baumannii, Acinetobacter calcoaceticus, Bordetella pertussis, Citrobacter diversus, Citrobacter freundii, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Providcncia stuartii, Serratia marcescens, Clostridium perfringens.

Indications

Treatment of mild, moderate and severe infections caused by strains of microorganisms sensitive to levofloxacin: acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarhalis

Pharmacological effect

Broad-spectrum antimicrobial agent, fluoroquinolone. Acts bactericidal. Blocks DNA gyrase (topoisomerase II) and topoisomerase IV, disrupts supercoiling and cross-linking of DNA breaks, inhibits DNA synthesis, causes profound morphological changes in the cytoplasm, cell wall and membranes.

Active against Enterococcus faecalis, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus agalactiae, Viridans group streptococci, Enterobacter cloacae, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter sakazakii, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Klebsiella oxytoca, Legionella pneumoniae, Moraxella catarrhalis, Proteus mirabilis, Pseudomonas aeruginosa, Pseudomonas fluorescens, Chlamydia pneumoniae, Mycoplasma pneumoniae, Acinetobacter anitratus, Acinetobacter baumannii, Acinetobacter calcoaceticus, Bordetella pertussis, Citrobacter diversus, Citrobacter freundii, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Providcncia stuartii, Serratia marcescens, Clostridium perfringens.

Special instructions

The infusion solution of the drug is compatible with the following infusion solutions: saline solution, 5% glucose solution, 2.5% Ringer’s solution with dextrose, combined solutions for parenteral nutrition (amino acids, carbohydrates, electrolytes). The infusion solution of the drug should not be mixed with heparin or solutions with an alkaline reaction (for example, sodium bicarbonate solution).

Active ingredient

Levofloxacin

Composition

Active substance – levofloxacin hemihydrate (in terms of levofloxacin) – 5 g.

Excipients:

sodium chloride – 900 mg,

lactic acid – 25 mg,

d/i water – up to 100 ml.

Contraindications

Hypersensitivity to levofloxacin or other quinolones; epilepsy; tendon lesions associated with a history of quinolone use; children and adolescents up to 18 years of age.

Side Effects

Allergic reactions: sometimes – itching and redness of the skin; rarely – anaphylactic and anaphylactoid reactions (manifested by symptoms such as urticaria, facial swelling, very rarely – a sudden drop in blood pressure and shock; in some cases – Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome) and exudative erythema multiforme.

Interaction

In combined treatment with fenbufen and similar NSAIDs, theophylline, the drug may increase the threshold for convulsive readiness.
Sucrafalt, iron salts and magnesium or aluminum containing antacids significantly reduce the effect of levofloxacin (the interval between doses of the drugs should be at least 2 hours).

Recommendations for use

The drug Levofloxacin is administered intravenously in a slow drip of 250-750 mg every 24 hours (a dose of 250-500 mg is administered over 60 minutes, 750 mg over 90 minutes). A subsequent transition to oral administration at the same dose is possible. The duration of treatment depends on the indications for use, as well as the sensitivity of the intended pathogen. The recommended dosage regimen should be strictly followed. It is recommended to continue use of the drug for 2-3 days after body temperature normalizes. Self-interruption or early termination of treatment with the drug is unacceptable.

Manufacturer

Kraspharma PJSC, Russia